Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial

Figure 2

Percentage (%) of office blood pressure (BP) responders (<140/90 mmHg in nondiabetics and <130/80 mmHg in diabetics or high-risk patients, or SBP reduction ≥20 mmHg or DBP reduction ≥10 mm) and of 24-hour BP responders (<130/80 mmHg or a SBP reduction ≥10 mmHg or a DBP reduction ≥5 mmHg) after 18 weeks of treatment with zofenopril 30–60 mg plus hydrochlorothiazide 12.5 mg (open bars) and irbesartan 150–300 mg plus hydrochlorothiazide 12.5 mg (full bars). Data are shown for the intention-to-treat population ( office BP set; ambulatory BP set).